DE69331942T2 - Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper - Google Patents

Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper

Info

Publication number
DE69331942T2
DE69331942T2 DE69331942T DE69331942T DE69331942T2 DE 69331942 T2 DE69331942 T2 DE 69331942T2 DE 69331942 T DE69331942 T DE 69331942T DE 69331942 T DE69331942 T DE 69331942T DE 69331942 T2 DE69331942 T2 DE 69331942T2
Authority
DE
Germany
Prior art keywords
inhibitor
antibody
cell adhesion
metastase
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69331942T
Other languages
English (en)
Other versions
DE69331942D1 (de
Inventor
Jyunko Hashino
Shinzo Oikama
Hiroshi Nakazato
Toshihiro Nakanishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daichi Suntory Pharma Co Ltd Tokio/tokyo Jp
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of DE69331942D1 publication Critical patent/DE69331942D1/de
Publication of DE69331942T2 publication Critical patent/DE69331942T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69331942T 1992-02-14 1993-02-12 Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper Expired - Fee Related DE69331942T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5955192 1992-02-14
PCT/JP1993/000182 WO1993016193A1 (en) 1992-02-14 1993-02-12 Cell adhesion inhibiting antibody and cell adhesion inhibitor containing the same

Publications (2)

Publication Number Publication Date
DE69331942D1 DE69331942D1 (de) 2002-06-27
DE69331942T2 true DE69331942T2 (de) 2002-10-02

Family

ID=13116505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69331942T Expired - Fee Related DE69331942T2 (de) 1992-02-14 1993-02-12 Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper

Country Status (9)

Country Link
US (1) US5648078A (de)
EP (1) EP0584368B1 (de)
JP (1) JP3483556B2 (de)
AT (1) ATE217909T1 (de)
DE (1) DE69331942T2 (de)
DK (1) DK0584368T3 (de)
ES (1) ES2177540T3 (de)
PT (1) PT584368E (de)
WO (1) WO1993016193A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503462A (ja) * 1998-02-12 2002-02-05 マクギル ユニバーシティ Ｃｅａ／ｎｃａに基づいた癌分化療法
EP1554309A2 (de) * 2002-10-03 2005-07-20 McGILL UNIVERSITY Antikörper und zyklische peptide, die cea ("carcinoembryonic antigen") binden und ihre verwendung als therapeutika gegen krebs
AU2011252699B2 (en) * 2010-05-11 2015-09-17 Governing Council Of The University Of Toronto The N-domain of carcinoembryonic antigen and compositions, methods and uses thereof
US9753036B2 (en) * 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
JPH0811075B2 (ja) * 1982-06-30 1996-02-07 雄治 松岡 単クローン性抗ｃｅａ抗体
JP2607492B2 (ja) * 1987-01-14 1997-05-07 サントリー株式会社 ヒト癌胎児性抗原
GB8800078D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JPH05119037A (ja) * 1991-08-08 1993-05-14 Suntory Ltd ヒト癌胎児性抗原の免疫測定法

Also Published As

Publication number Publication date
ES2177540T3 (es) 2002-12-16
PT584368E (pt) 2002-10-31
EP0584368B1 (de) 2002-05-22
JP3483556B2 (ja) 2004-01-06
DK0584368T3 (da) 2002-06-17
EP0584368A1 (de) 1994-03-02
US5648078A (en) 1997-07-15
DE69331942D1 (de) 2002-06-27
EP0584368A4 (en) 1996-07-03
WO1993016193A1 (en) 1993-08-19
ATE217909T1 (de) 2002-06-15

Similar Documents

Publication Publication Date Title
AU563644B2 (en) Hydroxy substituted peptides
ATE150975T1 (de) Peripheralisierung hämatopoietischer stammzellen
DK0765343T3 (da) Monoklonale antistoffer imod CD44v6
DE59609235D1 (de) Verwendung von aerogelen in der landwirtschaft
DE69414115T2 (de) Vitamin d analoge
DE68929384T2 (de) Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
IT8820741A0 (it) Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori.
ES2127531T3 (es) Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales.
DE69331942D1 (de) Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper
DE69132159T2 (de) Merosin, dafür kodierende nukleinsäuren, fragmente und deren verwendung
ATE156364T1 (de) Verwendung von lectinen für die behandlung von krankheiten
ES8707114A1 (es) Procedimiento para la obtencion de un anticuerpo monoclonal anti-alfa-amilasa
ATE310083T1 (de) Deprenyl induziertes protein
MX9606108A (es) Anticuerpos monoclonales contra cd44v6.
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DAICHI SUNTORY PHARMA CO., LTD., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee